| We disagree with the latest European Society of Cardiology guidelines about the preferred choice concerning P2Y12 inhibitors. Although the ISAR-REACT 5 data support the “one size does not fit all” concept, we believe that the guidelines do not provide sufficient evidence to support a preferred drug or strategy. |
| Giving a level-IIa recommendation for prasugrel over ticagrelor in patients with NSTE-ACS undergoing PCI seems overrated. In our opinion, equipoise remains, and more data are needed to settle the doubt between these two strategies. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.